Novartis signals beyond the news: 48+ signals from 7 sources
The latest Novartis signal on this page is from Sep 29, 2026 (Patents): "Novartis was granted a patent for selective protein-degradation compositions." The busiest sources: Glassdoor (15+), Website changes (15+) and Patents (10).
PublicPharmaceutical Manufacturing10,000+ employeesnovartis.comLinkedIn
- Signals
- 48+
- Sources
- 7
- Last 90 days
- 41
- Latest
- Sep 29, 2026
Other signals · latest 10
Latest Novartis signals by source
48+ signals for Novartis across 7 sources.
Patents · Patent grant
Novartis was granted a patent for selective protein-degradation compositions.
In September 2026 Novartis patented fusion-protein technology for targeted protein removal in drug discovery and therapeutic development.
- Patent title
- Compositions and methods for selective protein degradation
- Grant date
- Sep 29, 2026
- Inventors
- Seth Carbonneau, Marc Horst Peter Hild, Andrei Golosov, Nicole Renaud
Patents · Patent pace
NOVARTIS AG's patent output is steady: 71 grants in the past year, 5 in the past 30 days.
Over the past year NOVARTIS AG received 71 US patent grants, concentrated in networking / data transmission and health tech / medical informatics; the recent pace (13 in 90 days) is steady versus its trailing baseline.
- Grants, 12 months
- 71
- Grants, 90 days
- 13
- Grants, 30 days
- 5
- USPTO assignee
- Novartis AG
Reddit · Product change
Novartis has discontinued its Amyotrophic Lateral Sclerosis (ALS) program following a failure in its phase 2 clinical trial, adding to its R&D challenges.
Post: "Novartis ends ALS program after phase 2 flop, adding to R&D woes"
- Subreddit
- r/biotech
- Upvotes
- 56
- Comments
- 1
- Sentiment
- Negative
Glassdoor · Growth opportunities
Limited growth and promotion concerns reported by Novartis employees
Employees mention promotions are based more on tenure than performance, and non-PhDs need to prove themselves more, indicating a lack of clear advancement paths.
- Overall rating
- 4.0 of 5
- CEO approval
- 87%
- Reviews read
- 10
- Review window
- Aug 29, 2026 to Sep 9, 2026
Glassdoor · Poor work life balance
Multiple Novartis employees report suffering from work-life balance issues
Reviewers across different roles consistently mention high workloads, lack of balance, and the impact on morale, with one stating they cover tasks for two people.
- Overall rating
- 4.0 of 5
- CEO approval
- 87%
- Reviews read
- 10
- Review window
- Aug 29, 2026 to Sep 9, 2026
Website changes · Funding news
Novartis added prominent coverage of its second-quarter and first-half 2026 financial results.
Added homepage feature: “Novartis Financial Results – Q2 2026” and “Novartis announces the company’s financial results for the second quarter and first half of 2026,” with a link to the Q2 2026 results page.
- Page
- /
Website changes · Marketing shift
Novartis expanded its homepage messaging to emphasize its 30-year legacy, scientific discovery, and continued development of next-generation medicines.
Added homepage language including “30 years of Novartis, powered by 250 years of innovation” and “Rooted in a legacy of scientific discovery, Novartis continues to advance breakthrough medicines that redefine the future of care for patients.”
- Page
- /
Web traffic · Traffic decline
novartis.com traffic declined 28% to 1M monthly visits.
Minimal AI traffic at 0.8% (~10,201 visits). Top: chatgpt.com (73%), gemini.google.com (2%), claude.ai (0%).
- Monthly visits
- 1,319,655
- Month over month
- -28.5%
- 3-month change
- +34.4%
- Global rank
- 43,408
Employee growth · Several teams growing
Rapid growth across 15 departments with Education leading at 44% YoY growth.
Company is experiencing multi-department expansion, with 15 departments showing significant growth (≥5% YoY). The fastest growing department is Education at 44% growth, adding approximately 451 employees.
- Total headcount
- 74,718
- Company growth, 1 year
- +7%
- Median tenure
- 6.1 years
LinkedIn
Celebrating our environmental progress!
Celebrating our environmental progress! We are proud to be recognized by CDP, an independent non-profit organization enabling environmental disclosures, with double A list status for the fourth consecutive year – achieving the highest possible ‘A’ rating for our work in both climate and water. This recognition...
- Likes
- 402
- Comments
- 23
- Tags
- Sustainability, Corporate Strategy
Showing 10 of 48+ signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Novartis with the Signal API
One POST /v1/companies/enrich call with novartis.com returns Novartis signals from 14 more signal types (reddit-company, podcast-company, glassdoor-company and more), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{
"domain": "novartis.com",
"signal_types": ["reddit-company","podcast-company","glassdoor-company",
"product-reviews","linkedin-post-company","twitter-company-posts",
"youtube-company","website-intelligence","patents-company",
"federal-contract-award","conference-speaker","hackernews",
"producthunt-launch","seo-traffic"],
"limit": 20
}'Same industry
Other signals at related companies
Questions about Novartis other signals
What signals does Autobound track for Novartis besides news and filings?
What are people saying about Novartis online?
What do employees say about working at Novartis?
Has Novartis been granted patents recently?
Source. Reddit, podcasts, Glassdoor, product reviews, LinkedIn, X, YouTube, company websites, patents, federal contracts, conference talks, Hacker News, Product Hunt, web traffic and employee growth, from the Signal API.
Method. The latest 15 signals per source from the last 12 months. Posts that do not name the company, replies, repeats and unreadable rows are removed. Traffic and headcount keep their newest measure.
Data as of .